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AbstrAct
Objective To evaluate the effect of capnography 
monitoring on sedation-related adverse events during 
procedural sedation and analgesia (PSA) administered 
for ambulatory surgery relative to visual assessment and 
pulse oximetry alone.
Design and setting Systematic literature review and 
random effects meta-analysis of randomised controlled 
trials (RCTs) reporting sedation-related adverse event 
incidence when adding capnography to visual assessment 
and pulse oximetry in patients undergoing PSA during 
ambulatory surgery in the hospital setting. Searches for 
eligible studies published between 1 January 1995 and 
31 December 2016 (inclusive) were conducted in PubMed, 
the Cochrane Library and EMBASE without any language 
constraints. Searches were conducted in January 2017, 
screening and data extraction were conducted by two 
independent reviewers, and study quality was assessed 
using a modified Jadad scale.
Interventions Capnography monitoring relative to visual 
assessment and pulse oximetry alone.
Primary and secondary outcome measures Predefined 
endpoints of interest were desaturation/hypoxaemia 
(the primary endpoint), apnoea, aspiration, bradycardia, 
hypotension, premature procedure termination, respiratory 
failure, use of assisted/bag-mask ventilation and death 
during PSA.
Results The literature search identified 1006 unique 
articles, of which 13 were ultimately included in the meta-
analysis. Addition of capnography to visual assessment 
and pulse oximetry was associated with a significant 
reduction in mild (risk ratio (RR) 0.77, 95% CI 0.67 to 0.89) 
and severe (RR 0.59, 95% CI 0.43 to 0.81) desaturation, as 
well as in the use of assisted ventilation (OR 0.47, 95% CI 
0.23 to 0.95). No significant differences in other endpoints 
were identified.
Conclusions Meta-analysis of 13 RCTs published 
between 2006 and 2016 showed a reduction in respiratory 
compromise (from respiratory insufficiency to failure) 
during PSA with the inclusion of capnography monitoring. 
In particular, use of capnography was associated with less 
mild and severe oxygen desaturation, which may have 
helped to avoid the need for assisted ventilation.
Background and aims
The administration of procedural seda-
tion and analgesia (PSA) involves achieving 
a drug-induced depression in level of 
consciousness and pain to ensure the comfort 
and cooperation of patients undergoing 
non-surgical and minor surgical procedures. 
Significant adverse events associated with PSA 
are relatively rare but not inconsequential, 
and can include severe oxygen desatura-
tion, bradycardia, hypotension and cardiac 
arrest.1 2 Consensus dictates that levels of 
sedation are directly related to patient risk 
during PSA, as is the potential for unin-
tended progression from moderate to deep 
sedation.3 Generally speaking, most cardio-
pulmonary events associated with PSA stem 
from poor or absent ventilation cascading 
into hypoxia, tissue injury and cardiac 
decompensation (see online supplementary 
figure 1). In turn, maintaining patient safety 
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Research
Strengths and limitations of this study
 ► The studies included in the analysis were all 
published in 2006 or later, representing modern 
medical practice and providing clinically relevant 
evidence of improvements in patient safety with the 
use of capnography monitoring.
 ► The study findings further substantiate a previously 
published meta-analysis, which found that 
capnography monitoring was more likely to detect 
adverse events. It also suggests that superior 
detection may reduce the use of clinical interventions 
intended to rescue patients from potential adverse 
outcomes.
 ► The level of sedation employed in each study was 
not uniformly reported, resulting in a mixture of 
different sedation levels in the primary analysis 
and precluding an analysis of outcomes by sedation 
level.
 ► As with all meta-analyses, the study findings may 
be affected by publication, search or selection 
bias affecting the studies ultimately included in 
the analysis. Where possible, steps were taken to 
minimise the effects of bias on the analysis, but 
the degree to which these steps were successful is 
difficult to quantify.
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involves the identification of respiratory compromise to 
prompt the use of clinical intervention before further 
complications occur.4–9
In current clinical practice, patient monitoring during 
PSA often relies on visual assessment of ventilation and 
use of pulse oximetry, which reflects hypoxaemia.10–14 
To date, a mandate to include capnography in patient 
monitoring, as a means of early detection of alveolar 
hypoventilation, has remained a topic of debate.15 In 
particular, there has been a perceived gap between various 
study outcomes and evidence of improved patient safety. 
No studies have provided ‘hard proof’ that addition of 
capnography to patient monitoring may reduce severe 
morbidity and mortality during PSA (in part because of 
ethical considerations to ensure patient rescue). Previous 
efforts to use meta-analysis to determine the utility of 
capnography to identify clinically significant respiratory 
depression have been faulted for large heterogeneity and 
non-standard endpoints.16 17
The primary aim of the present systematic review and 
meta-analysis was to understand whether capnography 
added to patient monitoring only (consisting of pulse 
oximetry and visual inspection of ventilation) reduces 
the incidence (or odds) of adverse events during PSA 
based on randomised controlled trials (RCTs) of patients 
undergoing a variety of ambulatory surgical procedures. 
The analysis was based on the hypothesis that earlier 
and more sensitive detection of ventilatory changes with 
capnography may allow for more timely intervention and 
prevention of potential adverse events, such as cardiac 
dysrhythmias. Throughout the analyses, we sought to 
provide the highest level of synthesised evidence with 
respect to the clinical utility of capnography moni-
toring during PSA. To mitigate potential pitfalls due to 
non-standard endpoints, particular emphasis was placed 
on maintaining a consistent definition of adverse events 
across all studies included.
meThods
Literature searches were conducted in PubMed, the 
Cochrane Library and EMBASE. Search terms were a 
combination of MeSH (Medical Subject Heading) terms 
and free-text searches within the articles title and abstract. 
Searches aimed to identify all literature reporting on 
randomised, controlled trials in patients receiving seda-
tion during ambulatory surgery and in which visual 
assessment of ventilation and pulse oximetry monitoring 
(control) was compared with control plus capnography. 
‘Grey’ or unpublished literature (including congress 
abstracts) was included in the search strategy and, as the 
review protocol was not registered in advance, the full 
search strategy (see online supplementary table 1) and 
additional details are provided in the supplementary data. 
Only articles or abstracts published on or after 1 January 
1995 were included and all searches were performed 
on 15 January 2017. A previous systematic review in 
this area did not identify any study prior to 1995,16 and 
studies published prior to 1995 were considered unlikely 
to reflect modern clinical practice. No language exclu-
sion was applied and inclusion was not dependent on the 
capnography monitor in use. After duplicate removal, title 
and abstract screening (see online supplementary table 
2) was performed independently by RS and RFP using 
Sourcerer (Covalence Research Ltd, London, UK).18 Full-
text versions of all non-excluded articles were retrieved 
by MM and reviewed independently by RS and RFP. 
Data were then extracted independently by RS and RFP 
into data extraction forms in Microsoft Excel (Microsoft 
Corporation, Redmond, Washington). Any discrepancies 
in the extracted data were resolved by reference to the 
original study, reaching consensus between RS and RFP. 
All extracted endpoint data were reviewed by JRL and 
MMRFS for clinical utility to ensure that all synthesised 
data relate to clinically equivalent endpoints. Extracted 
data included the number of patients with events and the 
population at risk, in addition to items required to assess 
article quality and bias. Reference lists of included studies 
were not searched.
endpoints
Predefined endpoints of interest were desaturation/
hypoxaemia (the primary endpoint, with severe desat-
uration defined as SpO2 ≤85%), apnoea, aspiration, 
bradycardia, hypotension, premature procedure termi-
nation, respiratory failure, use of assisted/bag-mask 
ventilation and death during PSA. The protocol was left 
open for the analysis of other patient safety endpoints 
that were reported by ≥3 studies. Cardiac arrest and death 
were considered to be representative of severe morbidity 
and mortality. Notably, the present analysis examined 
individual endpoints as opposed to composite endpoints 
(eg, desaturation, apnoea or respiratory depression) and 
included analyses of more specific endpoints, such as 
oxygen desaturation <90% and <85%.
Quality and potential bias
Assessment of article quality was conducted on a study 
(as opposed to outcome) level using a modified Jadad 
score,19 with additional criteria added to make the adap-
tation specific to monitoring. The Jadad score assesses 
studies based on their design (randomised and blinded) 
and their reporting (all patients accounted for), with 
a maximal score of 5 (high quality) and a low score 
of 0 (low quality). Additional data included here were 
endpoint definitions, patient population, hospital loca-
tion at which patients underwent sedation and the staff 
responsible for monitoring. In line with the Jadad score, 
items related to trial design could score up to twice as 
highly as items relating to trial reporting. The reporting 
of the inclusion/exclusion criteria and endpoint defini-
tions scored one point each, and reporting the location 
of sedation, and the monitoring staff scored half-point 
each, making the maximal score 8 (high quality). For 
the purposes of analysing study quality, studies with 
scores of 0–5.5 were considered to be low quality, while 
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studies scoring 6.0–8.0 were designated as high-quality 
studies.
Risk of bias in results was evaluated independently 
from the quality assessment through the declaration of 
funding sources and conflicts of interest. If the study was 
funded by industry then the study scored 2 , any conflicts 
of interest declared relating to industry funding outside 
of the current research publication scored 1. A study with 
low potential for bias, therefore, would have a score of 
0. A high potential for bias was defined as a score of 3, 
while a score of 1–2 was considered to indicate moderate 
potential for bias. The absence of industry funding was 
not taken to signify an absence of bias, but the presence 
of industry funding or conflicts of interest was assumed to 
be an indicator of bias.20
analysis
Data extraction, initial data consolidation and summary 
statistics were performed in Microsoft Excel. Data for 
each endpoint were subsequently entered into Review 
Manager V.5.3.4 for results synthesis.21 Heterogeneity of 
data was evaluated using χ2 and I2 statistics presented by 
Review Manager V.5.3.4, with I2 further categorised by 
the tentative Higgins et al heterogeneity categories of 
low, moderate and high.22 The meta-analysis performed 
calculated the mean intervention effect across all eligible 
studies using (after analysis of heterogeneity) a random 
effects model as described by DerSimonian and Laird.23 
An estimate of between-study variation was provided by 
the Mantel-Haenszel methodology.24
The main outcome reported for each endpoint was the 
pooled mean risk ratio (RR), except when the incidence 
of rare endpoints was less than 1%. In these instances, the 
Peto method was used as a fixed-effects model designed 
specifically for analysis of rare endpoints. The Peto 
method only reports an OR and, to allow comparison 
between all endpoints analysed, the pooled mean OR was 
therefore also presented for all analyses. In all cases, the 
95% CI is reported to allow assessment of significance.
Sensitivity analyses were specified a priori and the tested 
conditions were: (1) inclusion of high-quality studies 
only; (2) inclusion of only moderate sedation; (3) inclu-
sion of only studies with low risk of bias; (4) inclusion 
of only studies based in the USA; (5) inclusion of only 
studies based in Europe; (6) exclusion of paediatric data; 
(7) exclusion of gender-specific studies; (8) exclusion 
of data in patients <30 years of age. No formal statistical 
comparisons were made between sensitivity analyses, and 
intervention effects were not calculated for the excluded 
studies, thereby mitigating the introduction of type 1 
error into the analysis.
Patient involvement
No patients, service users or laypeople were involved in 
the design or conduct of this study. Outcome measures 
were all related to patient safety during PSA, but were 
not developed based on an explicit elicitation of patient 
priorities, experience and preferences.
resulTs
Literature searches of PubMed, the Cochrane Library 
and EMBASE returned 385, 87 and 804 articles, respec-
tively. After removal of 270 duplicates (62 Cochrane, 208 
EMBASE), 1006 articles remained for abstract screening. 
Although reasons for exclusion varied (see online supple-
mentary table 2), the two independent reviewers agreed 
upon a total of 24 articles to be retained for full-text review 
(Cohen’s kappa, 1.0). Eleven articles were excluded 
on full-text review (see online supplementary figure 2) 
because they: reported duplicate data (n=5), did not 
report patient safety data (n=3), did not include sedation 
(n=2) or compared two different capnography monitors 
(n=1). The 13 articles included for analysis are presented 
in table 1 and included data on 14 patient groups (one 
study, published by Mehta et al, provided separate data on 
colonoscopy and esophagogastroduodenoscopy).25 All 
studies reported desaturation endpoints, although the 
definition did vary by study (see online supplementary 
table 3). Other endpoints were heterogeneously reported, 
but were in most cases reported by ≥3 studies making 
meta-analysis feasible as per the predefined protocol. 
Results reported are from random-effects models unless 
otherwise stated. Results for the use of supplemental 
oxygen and hypotension are provided in the supplemen-
tary information only (see online supplementary figures 
3 and 4, respectively).
mild desaturation
All studies (table 1) reported mild desaturation, with 
the definition varying from an oxygen saturation (SpO2) 
of <95% to <90% for ≥15 s.5 6 25–35 There was evidence 
of heterogeneity (I2=50%, moderate) in the primary 
analysis. Results indicated that capnography signifi-
cantly reduced the incidence of mild desaturation (RR 
0.77, 95% CI 0.67 to 0.89; OR 0.67, 95% CI 0.55 to 0.82; 
figure 1). The odds of a mild desaturation event were 
reduced by over 30% when capnography monitoring is 
used, compared with no use of capnography. If only high-
quality studies (n=7, eight populations) were included 
(see online supplementary figure 5), there was evidence 
of heterogeneity (I12=61%, moderate) but the outcome 
did not differ: RR 0.75 (95% CI 0.62 to 0.92; OR 0.63, 
95% CI 0.48 to 0.83). Using exclusively studies with 
equivalent definitions of mild desaturation (<90%, n=8, 
nine populations), evidence of heterogeneity (I2=57%, 
moderate) was still present; the RR estimated from these 
studies was 0.76 (95% CI 0.65 to 0.89; OR 0.64, 95% CI 
0.51 to 0.80).
severe desaturation
Seven studies, of which four were classified as high quality, 
reported severe desaturation.5 25 27–30 34 All but one of the 
studies defined severe desaturation as SpO2 </≤85%. The 
analysis for this endpoint was aligned with the significant 
reduction in the odds of mild desaturation with the inclu-
sion of capnography, with an RR of 0.59 (95% CI 0.43 
to 0.81) and OR of 0.55 (95% CI 0.38 to 0.78). As with 
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Figure 1 Severe and mild desaturation are significantly reduced with capnography monitoring. The risk ratios for the endpoints 
of mild desaturation (A) and severe desaturation (B) are presented. M-H, Mantel-Haenszel.
mild desaturation, there was evidence of heterogeneity 
(I2=47%, moderate).
Synthesising estimates from high-quality studies 
supported the analysis of all studies, the RR of 0.57 
(95% CI 0.36 to 0.92) and OR of 0.53 (95% CI 0.31 to 0.89) 
reducing by 0.02 and the CIs widening (see online supple-
mentary figure 6). There was moderate heterogeneity 
between studies (I3=64%, moderate). Focusing on the six 
studies reporting an endpoint of SpO2 </≤85%, there 
was moderate heterogeneity and the RR was estimated 
at 0.56 (95% CI 0.41 to 0.78). Overall, a 40% reduction 
in the incidence of severe desaturation events would be 
expected with the use of capnography monitoring rela-
tive to standard of care.
Bradycardia
Six studies, three of high quality, reported bradycardia 
outcomes.25 28–30 33 34 The definition of bradycardia (heart 
rate <50 bpm) was consistent among five of the six trials 
and there was no evidence of heterogeneity between 
the studies (I2=0%, low). In four studies, the incidence 
of bradycardia was higher in the capnography arm 
compared with the control arm and overall, capnography 
monitoring was associated with a non-significant increase 
in bradycardia (RR 1.15, 95% CI 0.89 to 1.48; OR 1.16, 
95% CI 0.88 to 1.54) and outcomes were not affected by 
the inclusion of only high-quality studies or only studies 
with low risk of bias (see online supplementary figure 7).
apnoea
Apnoea was less widely reported or reported in combina-
tion with disordered respiration. Comparable endpoints 
were reported in five studies, of which three were high 
quality.5 6 25 33 34 There was substantial heterogeneity in the 
apnoea outcomes (I2=92%, high) and the analysis yielded 
a non-significant RR of 1.17 (95% CI 0.72 to 1.89). In an 
analysis including exclusively high-quality studies, the 
RR favoured capnography but remained non-significant 
at 0.89 (95% CI 0.64 to 1.23; see online supplementary 
figure 8).
There was one clear outlier in the apnoea analysis, 
with data from Klare et al reporting an RR of 11.71 (95% 
CI 5.30 to 25.90).34 Apnoea in this study was undefined 
for the standard of care arm, but in the capnography 
arm the apnoea criterion was the absence of exhaled 
CO2 for ≥15 s. Different criteria between trial arms 
may explain the large difference in detected apnoea, 
and capnography would be expected to detect apnoea 
earlier than standard of care monitoring. Excluding 
this study from the analysis resulted in an RR of 0.85 
(95% CI 0.65 to 1.12; OR 0.73, 95% CI 0.43 to 1.24).
assisted ventilation
Only one study reported ‘respiratory failure,’ which was 
treated with assisted bag-mask ventilation.28 In contrast, 
the number of studies (n=6) reporting assisted and/
or bag-mask ventilation was sufficient to perform a 
meta-analysis of this endpoint as a surrogate for respira-
tory failure.5 28 29 31 32 34 Due to the low number of events, 
a Peto fixed-effects OR model was used to assess this 
endpoint. Analysis found no evidence of heterogeneity 
(I2=0%, low) and demonstrated a significant reduction 
in assisted ventilation with capnography monitoring 
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Figure 2 The need for assisted ventilation is reduced with capnography monitoring. The ORs for the assisted ventilation 
endpoint are presented for all studies (A), high-quality studies (B), studies with low risk of bias (C) and studies with the endpoint 
specified as bag-mask ventilation (D). 
(OR 0.47, 95% CI 0.23 to 0.95). In every case, the need 
to provide assisted ventilation was lower in the capnog-
raphy arm compared with the control arm (figure 2). 
Three studies were of high quality and had a low risk of 
bias, meta-analysis of these studies gave an OR of 0.56 
(95% CI 0.27 to 1.20). Three studies specified assisted 
ventilation as bag-mask ventilation, and for this subset 
of studies the OR was 0.56 (95% CI 0.26 to 1.25).
sensitivity analyses
A series of sensitivity analyses were conducted in which 
the studies included in the estimation of the RR and OR 
were varied. The results of these analyses are presented in 
table 2 and show that results were generally robust to the 
studies included for data synthesis. There were limited 
data available to assess the impact of capnography moni-
toring during moderate sedation.
discussion
The findings of this meta-analysis of recent RCTs 
comparing visual assessment of ventilation and pulse 
oximetry monitoring with and without capnography 
during PSA showed that the odds of oxygen desatura-
tion and assisted ventilation events were significantly 
reduced with the use of capnography. Other endpoints 
that could be affected by capnography monitoring were 
also considered but no significant differences were 
detected. Of potential clinical importance was the consis-
tency of data across multiple high-quality clinical trials 
reporting a reduced incidence of assisted ventilation with 
capnography monitoring. No endpoints assessed in the 
meta-analysis indicated significant patient safety concerns 
with capnography.
Physician concerns for patient safety often focus on 
mortality and severe morbidity. Using the need for 
assisted ventilation as a proxy, there was evidence that 
severe morbidity may differ between control and capnog-
raphy arms in the present meta-analysis. Although we note 
that no single trial showed a significant difference in this 
outcome, the information now exists to perform a power 
calculation to determine the number of patients that 
would be required to be enrolled in a prospective clin-
ical trial to demonstrate a significant reduction in patient 
harm. The incidence of mortality and severe morbidity 
events during nurse-administered PSA has been reported 
to be 1 event per 303 procedures (0.33%).36 Taking this 
value along with the assumption that capnography could 
prevent 50% of events (in line with the estimate from 
our analysis), and employing trial-size estimation meth-
odology reported by Zhong showed that 27 726 patients 
would be required to demonstrate statistical superiority.37 
Switching to an assumption that capnography would 
prevent 10% of events, the required enrolment would 
be >900 000 patients. As such, we submit the feasibility of 
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performing superiority trials is low, and leaves meta-anal-
yses, such as the present study, as the only viable alternative 
for determining the impact of capnography on such crit-
ical patient endpoints.
Our analysis is timely given the ongoing debate as to 
whether the addition of capnography to patient moni-
toring during PSA adds value.17 Without doubt, potential 
technical and financial burdens have further limited 
adoption of capnography monitoring in various clinical 
settings.15 17 Nevertheless, it is important to recognise 
that patient safety benefits may offset a number of these 
concerns if the outcomes are applicable to current medical 
practice.38 In this regard, the 13 trials identified in the 
present analysis were all recent, with the first published 
study identified in 2006. The data used in the present 
meta-analysis therefore represent modern medical prac-
tice, and provide consistent evidence of improvements in 
patient safety with the use of capnography monitoring.
Our findings further substantiate a previously published 
meta-analysis (Waugh et al), which found that capnog-
raphy monitoring was more likely to detect adverse events, 
but was faulted for large endpoint heterogeneity.16 In the 
present meta-analysis, we focused on identifying high-
quality studies, and on maintaining consistent definitions 
across all included studies. The results show that the addi-
tion of capnography to patient monitoring during PSA 
results in increased patient safety, with significant reduc-
tions in mild and severe levels of oxygen desaturation, as 
well as the need for assisted ventilation.
A recent meta-analysis by Conway et al reported a signif-
icant benefit with capnography during colonoscopy only 
with respect to hypoxaemia.39 However, the Conway et al 
meta-analysis identified and screened only a fraction of 
the literature included in the present analysis (388 papers 
in Conway et al, compared with 1006 papers in the current 
study) and retrieved fewer RCTs (6 vs 13). In addition, 
Conway et al excluded two trials in which an independent 
observer monitored capnography output for all patients, 
and signalled to the attending physician when respira-
tory compromise was identified with capnography either 
immediately (intervention) or after a specified delay 
(control).5 6 The rationale for this study design was to 
prevent unnecessary patient harm while avoiding inves-
tigator bias. Based on our understanding, the two trials 
excluded in the Conway et al analysis were the only studies 
in the literature that could be considered fully blinded. 
Among the other studies, the attending physician would 
have been aware of study arm assignment.27 29 32
As with other major assessment tools such as Delphi, 
Consort and the Cochrane risk of bias tool, blinding is an 
integral part of the Jadad score used in the present anal-
ysis.19 40 The trials excluded from the Conway et al analysis 
are both considered to be ‘high quality’ in the present 
analysis, driven in part by the inclusion of blinding in 
the scoring methodology. Other included trials, though 
potentially more representative of current clinical prac-
tice, are open to operator bias, the consequences of which 
were demonstrated in 2012 by Veerus et al.41
The Jadad score is a widely used score of clinical study 
quality.42 In the present analysis, the scale was modified 
to make it more applicable to monitoring studies by 
including parameters such as monitoring staff and proce-
dure location. One potential limitation of the present 
quality appraisal approach was the lack of validation of the 
modifications to the Jadad score; however, as might have 
been anticipated, the modified score does significantly 
correlate with the raw Jadad score (adjusted R2=0.93, 
p<0.01). Furthermore, analysis of mild desaturation 
data using a mixed model that took the Jadad score or 
the modified Jadad score as a covariate, found no signif-
icant difference between models and the heterogeneity 
accounted for (approximately 50% for both models).
Another ongoing debate in PSA concerns the clinical 
importance of seemingly minor endpoints, such as mild 
desaturation (oxygenation <90% for 15 s). Although 
such endpoints have traditionally been considered tran-
sient and perhaps clinically insignificant during PSA, 
several recent studies of common intraoperative events 
have suggested that mild desaturation may have more 
impact on postsurgical outcomes than has previously 
been recognised.43 For example, Dunham et al looked 
retrospectively and determined that surgical patients who 
experienced perioperative hypoxaemia/desaturation 
had a significant increase in their length of hospital stay 
(+2.0 days, p<0.0001).44 In turn, the impact of transient 
desaturation during PSA in terms of patient outcomes 
and quality of life may yet be of importance but remains 
to be determined.
Over all of the randomised trials included in the analysis, 
there was one report of patient mortality, which occurred 
in the standard of care arm of the trial presented by Klare 
et al.34 Only the largest trials reported any requirement 
for assisted/bag-mask ventilation, which is used as an 
intervention during, and thereby is a proxy measure for, 
potentially life-threatening events. Although it is widely 
accepted that much larger studies would be useful to 
assess whether or not capnography monitoring impacts 
patient major morbidity and mortality, there has been 
no determination to date of the trial size that would be 
required. Power calculations furthered by our meta-anal-
ysis suggest such a large RCT is likely to be impractical.
For healthcare providers, the most significant finding 
may be the consistency of data surrounding assisted venti-
lation and severe oxygen desaturation with capnography. 
Two closed claim reviews both found that inadequate 
oxygenation/ventilation was the most frequent event 
leading to a claim related to PSA outside the operating 
room.45 46 The potential cost burden is demonstrated by 
the median cost of a claim settled being US$330 000 (in 
2007 US$).45 The authors reported that better monitoring 
would have reduced the number of claims.45 A similar 
message was returned following the fourth National Audit 
Project in the UK, which analysed major complications of 
airway management in the National Health Service and 
determined that capnography monitoring could have led 
to earlier identification of airway obstruction, potentially 
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preventing 74% of death or neurological injury cases.47 48 
Studies included in the present meta-analysis reported 
that disordered ventilation as detected by capnography 
preceded desaturation events by 30–60 s.
The meta-analysis did find an increase in bradycardia 
with capnography monitoring that was non-significant. 
However, in each of the trials reporting higher incidence 
the patients in the capnography arm had larger doses 
and increased use of multiple agents for inducing PSA. 
Such confounding is plausible, may not be unusual and 
was discussed as possible factor in the trial outcomes by 
Campbell et al.49 All other findings of the current analysis 
were in line with expectations around the potential bene-
fits of capnography; as further substantiated by the results 
of our meta-analysis, earlier identification of respiratory 
compromise appears to result in more timely interven-
tion and prevention of its escalation into patient harm.
As with all data synthesis projects, the present study is 
only as accurate and reliable as the data underlying it. In 
the literature, there are examples of newly published clin-
ical trials that do not align with the results of published 
meta-analyses, and meta-analysis results changing on the 
publication of new data.50 51 The systematic nature of 
study identification and inclusion criteria in the present 
analysis was designed to identify all available literature 
and provide the most robust estimates of intervention 
effect. However, the included studies came from a variety 
of hospital settings, in which the rate of patient safety 
events might vary. This is apparent in the clinical trial 
results presented by Mehta et al, where colonoscopy 
and esophagogastroduodenoscopy were assessed inde-
pendently due to differences in outcomes.25 Analyses 
for particular settings were undertaken, but were then 
limited by reduced data availability. In total, this analysis 
represented 5460 patients (control 2755 and capnog-
raphy 2705) over 13 studies. Between trials, the number 
of patients enrolled varied between 132 and 986. Notably, 
of the six studies that identified rare outcomes (eg, use of 
assisted ventilation), five enrolled >500 patients.
conclusions
The results of this comprehensive meta-analysis of clinical 
trials provide clear and consistent evidence of decreased 
respiratory compromise when capnography monitoring 
is used during PSA. Specifically, the analysis identified a 
statistically significant and clinically meaningful reduc-
tion in mild and severe oxygen desaturation, as well as in 
assisted ventilation. Large, well-designed RCTs to provide 
direct links between use of capnography and reduction 
in patient harm may not be feasible. In turn, calls for this 
type of primary evidence may delay adoption of capnog-
raphy monitoring during PSA as a valuable tool for early 
intervention and improved patient safety.
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